Glioma
Conditions
Keywords
Glioma, Magnetic resonance spectroscopy, Methionine, PET/CT
Brief summary
MET PET and MRS are often performed as imaging tool for the differential diagnosis of gliomas. But both techniques have limitations causing misdiagnosis; thus, the investigators tried to combine these two imaging tools to study whether the combination of MET PET and MRS could raise the diagnosis ability of the radiological diagnosis of gliomas.
Interventions
OTHERtumors are confirmed by surgery and pathology
Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
Sponsors
Huashan Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with non-enhancing supratentorial lesions shown by contrast-enhanced MRI 2. No surgery, chemotherapy or radiotherapy history 3. All patients gave written informed consent.
Exclusion criteria
1. Patients with infratentorial Neoplasms 2. Patients with enhancing supratentorial lesions 3. Recurrent gliomas after surgery 4. Primary gliomas with history of radiotherapy or chemotherapy 5. History of malignant tumours at any body site 6. Inability to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity of the combination of MRS and 11C-MET PET/CT | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| The relationship between 11C-MET PET/CT results and molecular pathogeneses | 5 years |
Countries
China
Outcome results
None listed